JMP Securities Lowers Lantheus (NASDAQ:LNTH) Price Target to $112.00

Lantheus (NASDAQ:LNTH) had its price target cut by investment analysts at JMP Securities from $125.00 to $112.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the medical equipment provider’s stock. JMP Securities’ price objective suggests a potential upside of 23.47% from the company’s current price.

A number of other equities analysts have also recently commented on LNTH. Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.38.

Lantheus Stock Down 0.5 %

NASDAQ:LNTH traded down $0.46 during mid-day trading on Thursday, hitting $90.71. 1,631,048 shares of the company’s stock traded hands, compared to its average volume of 984,516. The company has a fifty day moving average of $108.04 and a 200 day moving average of $95.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a market capitalization of $6.30 billion, a P/E ratio of 14.89 and a beta of 0.51. Lantheus has a twelve month low of $50.20 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $378.73 million for the quarter, compared to the consensus estimate of $373.58 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. On average, analysts forecast that Lantheus will post 5.99 EPS for the current year.

Insider Activity

In other Lantheus news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently modified their holdings of LNTH. Daiwa Securities Group Inc. acquired a new stake in shares of Lantheus in the 1st quarter valued at $1,269,000. Moloney Securities Asset Management LLC acquired a new position in Lantheus in the third quarter valued at approximately $1,066,000. Nordea Investment Management AB raised its holdings in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after purchasing an additional 14,147 shares during the period. Hancock Whitney Corp raised its holdings in Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 14,639 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Lantheus in the second quarter worth $290,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.